SCHEMBL5136549

SCHEMBL5136549

CCCCn1c(CN(C/C=C\c2cccc(Br)c2)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.49
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
ALDH1A1 P00352 1/20 0.34
F2R P25116 3/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
ATM Q13315 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136553 1.00 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL5134608 0.89 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL5134610 0.89 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL5136279 0.89 C5AR1 (0.48) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5136277 0.89 C5AR1 (0.48) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5135814 0.88 C5AR1 (0.48) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5135817 0.88 C5AR1 (0.48) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5135160 0.87 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL5135157 0.87 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL5135424 0.87 C5AR1 (0.46) C5AR1HTR2AHTR2CHTR2BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed